The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

1.0 Checking for updates and scope: before scope consultation (to be completed by the Developer and submitted with the draft scope for consultation)

1.1 Have any potential equality issues been identified during the check for an update or during development of the draft scope, and, if so, what are they?

No equalities issues were identified during the update surveillance process. During scoping the following groups were identified as requiring consideration:
- people of West African and Caribbean descent in the context of management of a higher incidence of hypertension and increased risk of stroke or heart failure, and different response to some commonly used anti-hypertensive therapies.
- people of Indian descent in the context of increased risk of renal and cardiovascular disease, especially in people with diabetes
- people aged 80 years or older where treatment may impact on specific co-morbidities seen in this cohort as compared to the younger population.
1.2 What is the preliminary view on the extent to which these potential equality issues need addressing by the Committee? For example, if population groups, treatments or settings are excluded from the scope, are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

This guideline will update the previous NICE guidance on Hypertension and will consider the above population groups within the review questions as relevant.

Pregnant women and women planning on becoming pregnant are excluded from the scope. Use of pharmacological agents in pregnancy is subject to specific regulatory guidance. The management of hypertension in pregnancy is a highly specialist area best addressed in specific guidance on management of medical conditions in obstetrics.

Completed by Developer: Serena Carville, Guideline lead

Date: 24/05/17

Approved by NICE quality assurance lead: Kay Nolan

Date: 08/06/2017